Key statistics
SmartText not available for this item.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.00 |
---|---|
High | 0.184 |
Low | 0.184 |
Bid | -- |
Offer | -- |
Previous close | 1.47 |
Average volume | -- |
---|---|
Shares outstanding | 837.66k |
Free float | 802.29k |
P/E (TTM) | -- |
Market cap | 2.55m USD |
EPS (TTM) | -24.17 USD |
Data delayed at least 15 minutes, as of Sep 01 2023 07:09 BST.
More ▼
Announcements
- Sonnet BioTherapeutics Reports Third Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update
- Sonnet BioTherapeutics Reports Encouraging Data from Phase 1b/2a Clinical Trial of SON-080 in Chemotherapy-Induced Peripheral Neuropathy (CIPN) That Support Advancement into Phase 2 Study
- Sonnet BioTherapeutics Announces Exercise of Warrants for $3.4 Million in Gross Proceeds
- Sonnet BioTherapeutics Announces the Generation and Characterization of Two Novel Immunotherapeutic Pipeline Drug Candidates, SON-1411 and SON-1400, Each Containing a Variant IL-18 Domain
- Sonnet BioTherapeutics to Present SB221 as a Trial in Progress at the ASCO 2024 Annual Meeting
More ▼